Announcement on Convening Performance Briefing for 2025 and Q1 2026
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
Announcement on Convening Performance Briefing for 2025 and Q1 2026
Filed with SSE · · 2 pages · Chinese
Release
Zhejiang Jiuzhou Pharmaceutical Co., Ltd. on 6ix
Earlier from Zhejiang Jiuzhou Pharmaceutical
- Announcement on Application for Bank Credit with Self-owned Assets
- Announcement on Receipt of a No-objection Letter from the Shanghai Stock Exchange for the Controlling Shareholder's Issuance of Exchangeable Corporate Bonds
- Announcement on Obtaining the European CEP Certificate for Chemical Active Pharmaceutical Ingredient
- Announcement on Obtaining Drug Registration Certificate by the Wholly-owned Subsidiary
- Announcement on Progress in Opening a Special Settlement Account for Cash Management Products of Raised Funds and Using Temporary Idle Raised Funds for Cash Management
Later from Zhejiang Jiuzhou Pharmaceutical
- Announcement on Redemption of Idle Raised Funds Used for Cash Management upon Expiration and Continuously Conducting Cash Management
- Announcement on Redemption at Maturity of Partial Idle Raised Funds Used for Cash Management
- Announcement on Notifying Creditors of Cancellation of Repurchased Shares
- Announcement on Resolutions of the 21st Meeting of the 8th Board of Directors
- Announcement on the Company's Receipt of the Notice of Approval for Marketing Application of Chemical APIs
Follow Zhejiang Jiuzhou Pharmaceutical into a list and get an email when it puts out news.
Follow Zhejiang Jiuzhou Pharmaceutical